Dual Immunotherapy Shows Activity in Clear Cell Gynecologic Cancers

Dual Immunotherapy Shows Activity in Clear Cell Gynecologic Cancers (Medage today) – The nivolumab (opdivo) plus ipilimumab (yervoy) has shown significant activity in patients with light gynecological cell carcinomas, according to the results of a phase II non -randomized trial. Among 26 patients evaluated with …

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button